Most patients with atrial ®brillation should be considered for antithrombotic therapy. In a retrospective survey we investigated practice in two hospitals. For patients at high risk, established guidelines recommend warfarin, or aspirin if anticoagulants are contraindicated; for those at medium risk, either may be used.
INTRODUCTION
Atrial ®brillation (AF) is the most common sustained cardiac arrythmia in clinical practice and is associated with excess mortality 1 . The overall annual risk of stroke in AF is 4.5%, and warfarin therapy reduces this to 1.4%. In patients at very high risk of stroke it is even more effective, reducing the annual rate from 12% to 5% 2 . This has to be set against a small increase in haemorrhage, about 1.3% compared with 1% in controls. Published guidelines indicate that most patients with AF should be considered for antithrombotic therapy. We conducted a retrospective survey of hospital practice.
METHODS
Patients discharged with the diagnosis of AF during 1997± 1998 in two hospitals over a three-month period were included (a teaching hospital and a district general hospital). Notes were selected by means of the coding list, with AF as either a primary or a secondary diagnosis. Information was gathered from both inpatient and outpatient follow-up notes. The diagnosis of AF was con®rmed from electrocardiographic ®ndings and was classi®ed into acute, chronic or paroxysmal AF from the discharge summary and the clinical history. Associated risk factorsÐnamely, hypertension, diabetes, transient ischaemic attacks, cerebrovascular accidents, other thromboembolic events, ischaemic heart disease and left ventricular failureÐwere noted. Chronic AF and paroxysmal AF were considered to carry similar risks of stroke 2 . Patients receiving anticoagulation for prosthetic valves or vascular grafts were excluded. Patients were then classi®ed into high, medium or low risk according to the then established guidelines (Box 1) 3, 4 .
We assessed the antithrombotic therapy after risk strati®cation. Any documented reason for not giving secondary prophylaxis was noted. If none was recorded, possible contraindications such as previous bleed, active gastrointestinal ulcer, iron-de®ciency anaemia, chronic confusion, recurrent falls, allergy or patient's refusal were looked for. Patients with any of the above were judged unsuitable for anticoagulation. Wherever warfarin was contraindicated, suitability for aspirin was assessed. Any complications due to antithrombotic therapy were noted.
RESULTS
We identi®ed 156 who had had AF ( Table 1) . Most of them (76%) were in the high-risk group, for which the mean age was 79 years (range 57±92). The AF was chronic in threequarters. 67 patients (43%) had an echocardiogram. Cardioversion was not considered in any of the patients with chronic AF. We found no records of major bleeding. Treatment given was analysed according to the risk group (Table 2) . 31 patients were unsuitable for anticoagulation for the reasons shown in Table 3 . 18 of these were judged suitable for aspirin but only 8 received it.
DISCUSSION
The major limitation of this study is its retrospective nature. Since our sample is from two different hospitals, we believe it represents a wider practice pattern.
In Table 4 we summarize the bene®ts of antithrombotic therapy according to risk strati®cation. But schemes such as this are derived from clinical trials in which the patients may differ. For example, the mean age of patients who would bene®t from warfarin (79) was much higher than that of patients on warfarin in the pooled analysis (69). Nonetheless, we judge that antithrombotic therapy was underutilized.
Another question concerns the target international normalized ratio (INR), which was 2±3 in our series. This target for AF patients of all ages was derived by consensus from the results of ®ve clinical trials 2 . But this range may not be suitable for all patients over the age of 75. In a combined analysis of ®ve clinical trials, the rate of intracranial bleeding in patients over 75 was 0.3% per year. But, in the only clinical trial that speci®cally looked at patients above 75, with a mean INR of 2.6, the rate of intracranial haemorrhage was 1.8% per year 5 . This obviously raises concern among physicians regarding the safety of an INR above 2.6 in elderly patients. The SPAF III trial 6 Even so, aspirin might have been given more often. Though less ef®cacious than warfarin, aspirin should be used whenever warfarin is contraindicated. We could not tell from the case notes why it was prescribed so little. In the medium-risk group, 23% of patients did not receive any antithrombotic therapy. One patient in the low-risk group was anticoagulatedÐprobably unnecessarily.
Risk strati®cation in older patients can be dif®cult because any minor disturbance in their functional status (such as infection or a fall) or mental capacity may make anticoagulation temporarily unsafe. So elderly patients on warfarin should be carefully monitored to avoid any complications due to anticoagulation. Medium-risk and low-risk patients should be assessed regularly for development of any risk factors that would warrant anticoagulation.
Although the argument for antithrombotic prophylaxis in AF is reiterated in every guideline it is still underutilized. We recommend that, when there are reasons for nontreatment, these should be recorded in the patient's notes.
